Jennifer Gilbride
Publications by Year
Research Areas
Systemic Lupus Erythematosus Research, Bone health and osteoporosis research, Monoclonal and Polyclonal Antibodies Research, Bone health and treatments, Liver Diseases and Immunity
Most-Cited Works
- → Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis(2004)1,220 cited
- → Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study(2004)278 cited
- → A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis(2021)186 cited
- → Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus(2021)94 cited
- → Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population(2022)42 cited
- → Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus(2022)36 cited
- → Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry(2022)29 cited
- → 200 Efficacy and safety of belimumab in patients of black race with systemic lupus erythematosus: results from the EMBRACE study(2019)17 cited
- Novel ibandronate regimens in postmenopausal osteoporosis: design of the dosing intravenous administration (DIVA) study(2004)
- → Belimumab (BEL) Improves Renal Outcomes in Active Lupus Nephritis (LN): A Phase 3 Randomized, Placebo (PBO)-Controlled Trial(2020)